Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

About this update from Acadia Pharmaceuticals Inc.

SAN DIEGO, April 30, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis (ADP) and into early Phase 3 clinical study execution. Acadia has initiated a search for a new Head of Research and Development and is committed to identifying an experienced R&D leader who will build on the strong scientific foundation already in place. The Company continues to advance its clinical development programs as planned. All ongoing clinical trials, including the Phase 2 studies of remlifanserin in ADP and Lewy Body Dementia Psychosis (LBDP), continue to recruit and remain blinded, and the Company, including Dr. Thompson, does not yet know study outcomes. "Liz’s leadership has been instrumental in strengthening Acadia’s research and development organization, both scientifically and operationally, and in advancing a clear, disciplined R&D strategy across our pipeline," said Catherine Owen Adams, Chief Executive Officer of Acadia. "She has been a strong advocate for the patients we serve and at every step has ensured thoughtful execution and prioritization of our programs in neurological and rare diseases. Just as importantly, Liz fostered a culture of clarity, accountability, and engagement across R&D. We are grateful for her continued commitment to Acadia during the transition period and for her willingness to remain engaged as a consultant, providing continuity of scientific leadership and institutional perspective in support of our mission and, most importantly, the patients we serve." "Leading Acadia’s research and development organization has been a defining chapter in my career and one in which I take a great deal of pride," said Dr. Thompson. "We started from a great foundation, and have been able to build and strengthen the Acadia R&D team as well as make...

View stock analysis, news, and events for Acadia Pharmaceuticals Inc.